Cargando…

Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin

BACKGROUND: Dysregulation of microRNAs has been reported to be responsible for drug resistance of cancers. However, the association between aberrant expression of miR-26b and cisplatin resistance in non-small cell lung cancer (NSCLC) remains unclear. METHODS: PC9 and A549 were used to establish the...

Descripción completa

Detalles Bibliográficos
Autores principales: Zang, Shuzhi, Zhao, Shasha, Gao, Xinyuan, Li, Yunxia, Zhong, Chunlei, Gao, Jianlian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751336/
https://www.ncbi.nlm.nih.gov/pubmed/31686855
http://dx.doi.org/10.2147/OTT.S212649
_version_ 1783452603078672384
author Zang, Shuzhi
Zhao, Shasha
Gao, Xinyuan
Li, Yunxia
Zhong, Chunlei
Gao, Jianlian
author_facet Zang, Shuzhi
Zhao, Shasha
Gao, Xinyuan
Li, Yunxia
Zhong, Chunlei
Gao, Jianlian
author_sort Zang, Shuzhi
collection PubMed
description BACKGROUND: Dysregulation of microRNAs has been reported to be responsible for drug resistance of cancers. However, the association between aberrant expression of miR-26b and cisplatin resistance in non-small cell lung cancer (NSCLC) remains unclear. METHODS: PC9 and A549 were used to establish the cisplatin resistance models on NSCLC. Expression of miR-26b in cisplatin-resistant PC9 and A549 cells (PC9/R and A549/R) was detected by quantitative real-time PCR assays. Drug sensitivity and mitochondrial apoptosis were detected by Cell Counting Kit-8 assay and flow cytometry assay, respectively. The target relationship between miR-26b and tafazzin (TAZ) was validated by dual-luciferase reporter assay. RESULTS: Obvious downregulation of miR-26b was observed in PC9/R and A549/R cells. Restoration of miR-26b partially reversed the cisplatin resistance of PC9/R and A549/R cells. Expression of TAZ was increased in PC9/R and A549/R cells compared to the parental PC9 and A549 cells. Results of dual-luciferase reporter assays verified that TAZ was targeted by miR-26b. We showed that restoration of miR-26b expression inhibited the TAZ expression and thus expanded the mitochondrial pathway of apoptosis induced by cisplatin in PC9/R and A549/R cells. CONCLUSION: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting TAZ. miR-26b/TAZ axis may represent a potential strategy to reverse the cisplatin in NSCLC.
format Online
Article
Text
id pubmed-6751336
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-67513362019-11-04 Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin Zang, Shuzhi Zhao, Shasha Gao, Xinyuan Li, Yunxia Zhong, Chunlei Gao, Jianlian Onco Targets Ther Original Research BACKGROUND: Dysregulation of microRNAs has been reported to be responsible for drug resistance of cancers. However, the association between aberrant expression of miR-26b and cisplatin resistance in non-small cell lung cancer (NSCLC) remains unclear. METHODS: PC9 and A549 were used to establish the cisplatin resistance models on NSCLC. Expression of miR-26b in cisplatin-resistant PC9 and A549 cells (PC9/R and A549/R) was detected by quantitative real-time PCR assays. Drug sensitivity and mitochondrial apoptosis were detected by Cell Counting Kit-8 assay and flow cytometry assay, respectively. The target relationship between miR-26b and tafazzin (TAZ) was validated by dual-luciferase reporter assay. RESULTS: Obvious downregulation of miR-26b was observed in PC9/R and A549/R cells. Restoration of miR-26b partially reversed the cisplatin resistance of PC9/R and A549/R cells. Expression of TAZ was increased in PC9/R and A549/R cells compared to the parental PC9 and A549 cells. Results of dual-luciferase reporter assays verified that TAZ was targeted by miR-26b. We showed that restoration of miR-26b expression inhibited the TAZ expression and thus expanded the mitochondrial pathway of apoptosis induced by cisplatin in PC9/R and A549/R cells. CONCLUSION: Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting TAZ. miR-26b/TAZ axis may represent a potential strategy to reverse the cisplatin in NSCLC. Dove 2019-09-13 /pmc/articles/PMC6751336/ /pubmed/31686855 http://dx.doi.org/10.2147/OTT.S212649 Text en © 2019 Zang et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Zang, Shuzhi
Zhao, Shasha
Gao, Xinyuan
Li, Yunxia
Zhong, Chunlei
Gao, Jianlian
Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
title Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
title_full Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
title_fullStr Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
title_full_unstemmed Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
title_short Restoration of miR-26b expression partially reverses the cisplatin resistance of NSCLC by targeting tafazzin
title_sort restoration of mir-26b expression partially reverses the cisplatin resistance of nsclc by targeting tafazzin
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6751336/
https://www.ncbi.nlm.nih.gov/pubmed/31686855
http://dx.doi.org/10.2147/OTT.S212649
work_keys_str_mv AT zangshuzhi restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin
AT zhaoshasha restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin
AT gaoxinyuan restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin
AT liyunxia restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin
AT zhongchunlei restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin
AT gaojianlian restorationofmir26bexpressionpartiallyreversesthecisplatinresistanceofnsclcbytargetingtafazzin